Application 1063
Photodynamic therapy for Verteporfin (Visudyne) for Subfoveal choroidal neovascularisations (Commercial in Confidence)
Application No. | 1063 |
| Application Name and Project Officer | Photodynamic therapy for Verteporfin (Visudyne) for Subfoveal choroidal neovascularisations (Commercial in Confidence) |
| Advisory Panels | Dr Ray Kirk (Chair and MSAC member) Dr Terri Jackson (MSAC Member) Associate Professor Denis Stark (co-opted Ophthalmologist) Dr Alex Harper (Royal Australian and New Zealand College of Ophthalmologists nominee) Associate Professor Ian McAllister (Royal Australian and New Zealand College of Ophthalmologists nominee) Mr Frank Fisher (Consumer Health Forum of Australia) Associate Professor Justin O'Day (co-opted eye specialist) |
| Date Received by MSAC Secretariat | 11 November 2002 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | MSAC recommended on the strength of evidence pertaining to the safety, effectiveness and cost-effectiveness of photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation lesions, the current public funding arrangements remain unchanged. |
| Stage 4 - Decision | Endorsed by the Minister 11 March 2005 |
Page currency, Latest update: 02 November, 2006
